Join our daily newsletter At The Bell to receive exclusive market insights
- Medical imaging company Advanced Human Imaging (AHI) has signed a deal with U.S. pathology company Jana Care to integrate technologies
- Jana has developed and patented an on-device blood screening tool called Aina
- The blood test delivers rapid and accurate readouts that are valuable for health management apps like AHI’s CompleteScan
- Under the agreement, the parties will combine Jana’s Habits app into the CompleteScan platform, with the first demonstrable product expected in the third quarter
- Additionally, AHI will have an option to purchase a strategic interest in Jana
- On the market this morning, AHI is up 11.1 per cent and is trading at $1.75 per share
Advanced Human Imaging (AHI) has signed a deal with U.S. pathology company Jana Care to integrate technologies.
Jana has developed and patented an on-device blood screening tool called Aina.
Aina is the size of a matchbox and uses a very small strip of paper treated with analytes that react to a drop of blood from the user. The strip is inserted into the Aina device which then provides results and transfers the data to the user’s smartphone.
The data brings lab-quality blood tests to individuals, doctors, healthcare workers and their patients and avoids the need for patients to go to a medical facility to provide blood and then wait for the results over days.
The blood test delivers rapid and accurate readouts that are valuable for health management apps like AHI’s CompleteScan.
Under the agreement, the parties will combine Jana’s Habits app into the CompleteScan platform, with the first demonstrable product being made available in the third quarter.
AHI will include Jana’s Aina device as an add-on to its suite of healthcare information technologies that run on a user’s smartphone.
“The commercial distribution arrangement we have undertaken with Jana is an extremely important addition to the remote care and health assessment platform we are delivering to our partners and the vast communities they service around the world,” AHI CEO Vlado Bosanac said.
“I am excited with this latest partnership and how it brings AHI a full circle approach to individualized care and identification. My intention is to support all on-device capabilities by the close of 2021, with FaceScan, BodyScan, DermaScan, MSKScan and VeniScan,” he added.
Jana Care CEO Rajen Dalal says the parties’ technologies are the perfect fit.
“Jana Care’s quantitative digital fingerstick tests for heart, kidney, and diabetes, combined with AHI’s MultiScan suite of optical imaging applications using the smartphone, complete the circle to provide a 360- degree view of an individual’s health and wellness,” he said.
“COVID put to rest any lingering doubts there may have been regarding the potential value of remote monitoring with smartphone-based telemedicine and telediagnostics. We are only at the beginning of this digital health revolution and will see the impact of these technologies grow in the near future as they help reduce the progression of chronic disease and reduce healthcare costs,” he added.
Additionally, AHI will have an option to purchase a strategic interest in Jana.
On the market this morning, AHI is up 11.1 per cent and is trading at $1.75 per share at 11:40 am AEST.
